



(51) International Patent Classification:

C07D 239/28 (2006.01) **C07D 405/12** (2006.01)
C07D 239/38 (2006.01) **C07D 405/14** (2006.01)
C07D 239/42 (2006.01) **C07D 413/04** (2006.01)
C07D 239/47 (2006.01) **C07D 417/04** (2006.01)
C07D 239/48 (2006.01) **C07D 239/557** (2006.01)
C07D 239/58 (2006.01) **A61K 31/506** (2006.01)
C07D 401/14 (2006.01) **A61P 3/10** (2006.01)
C07D 403/04 (2006.01)

(21) International Application Number:

PCT/GB2009/050392

(22) International Filing Date:

20 April 2009 (20.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/046,836 22 April 2008 (22.04.2008) US
 61/140,201 23 December 2008 (23.12.2008) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GILL, Adrian, Liam** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **LEACH, Andrew** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **PACKER, Martin** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **SCOTT, James, Stewart** [GB/GB]; AstraZeneca R&D

Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **SÖRME, Pernilla** [SE/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **SWALES, John, Gibbin** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WHITTAMORE, Paul, Robert, Owen** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151-85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281



(57) Abstract: A compound of formula (I) and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11 β HSD1, processes for making them and pharmaceutical compositions comprising them are also described.